Cashu FinanceCashu Finance
  • Terminal
  • Spotlight
  • Cashu Research
Log inSign Up
← Back to Terminal
  1. Stocks
  2. Healthcare
  3. NASDAQ
  4. ALKS

Market Cap: $7.46B

AP

Alkermes plc

ALKS
NASDAQUSD
Purchase ALKS
OverviewNewsAnalyst ReportsFinancialsPolitician TradesInsider TradesExecutive
Cashu FinanceCashu Finance

By Cashu Finance. Providing market news, analysis, and research for investors worldwide.

Company

StocksAboutAdvertisersBrokersContact

Legal

Terms of ServicePrivacy Policy

© 2026 Cashu Technologies Pty Ltd. All rights reserved. Cashu Finance is a trademark of Cashu Technologies Pty Ltd.

The content published on Cashu Finance is for informational purposes only and should not be construed as investment advice, a recommendation, or an offer to buy or sell any securities. All opinions expressed are those of the authors and do not reflect the official position of Cashu Technologies Pty Ltd or its affiliates. Past performance is not indicative of future results. Investing involves risk, including the possible loss of principal. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Cashu Finance and its contributors may hold positions in securities mentioned in published content. Any such holdings will be disclosed at the time of publication. Market data is provided on an "as-is" basis and may be delayed. Cashu Technologies Pty Ltd does not guarantee the accuracy, completeness, or timeliness of any information presented.

Cashu Research is part of Cashu Technology Pty Ltd, which is an authorised representative (AR # 001318029) of Adviser Solutions Group Pty Ltd (ABN 88 601 875 521) (AFSL 485946) (ASG).

This material is general advice only and is not an offer for the purchase or sale of any financial product or service. The material is not intended to provide you with personal financial or tax advice and does not take into account your personal objectives, financial situation or needs. Although we believe that the material is correct, no warranty of accuracy, reliability or completeness is given, except for liability under statute which cannot be excluded. Please note that past performance may not be indicative of future performance and that no guarantee of performance, the return of capital or a particular rate of return is given by Cashu Technologies Pty Ltd, any of their related body corporates or any other person. To the maximum extent possible, Cashu Technologies Pty Ltd, their related body corporates or any other person do not accept any liability for any statement in this material.

–
–(–)

Open

$53.88

Prev. Close

$43.63

High

$54.17

Low

$53.60

Company Profile

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

CEO

Recently from Cashu

Alkermes Reports Positive Phase 2 Results for Narcolepsy Treatment Alixorexton

Alkermes Reports Positive Phase 2 Results for Narcolepsy Treatment Alixorexton

Alkermes plc (Ticker: ALKS) reports promising developments in its ongoing efforts to innovate treatment for narcolepsy type 2. The company recently revealed strong results from its phase 2 Vibrance-2…

Cashu Finance·4 months ago
Alkermes' Alixorexton Shows Promising Results for Narcolepsy Treatment in Phase 2 Trial

Alkermes' Alixorexton Shows Promising Results for Narcolepsy Treatment in Phase 2 Trial

Alkermes plc has recently released promising results from its phase 2 Vibrance-2 trial for alixorexton, an oral orexin 2 receptor agonist aimed at treating adults with narcolepsy type 2. The study ind…

Cashu Finance·4 months ago
Alkermes plc Attracts Institutional Interest and Positive Analyst Upgrades Amid Growth Prospects

Alkermes plc Attracts Institutional Interest and Positive Analyst Upgrades Amid Growth Prospects

Alkermes plc (Ticker: ALKS) experiences notable interest from institutional investors as recent filings reveal increased stakes and positive analyst ratings. Panagora Asset Management Inc. raises its…

Cashu Finance·4 months ago
Alkermes Awarded Orphan Drug Status for Alixorexton to Treat Idiopathic Hypersomnia

Alkermes Awarded Orphan Drug Status for Alixorexton to Treat Idiopathic Hypersomnia

Alkermes plc (Ticker: ALKS) recently celebrates a crucial achievement with the US FDA granting orphan drug designation for alixorexton, a treatment designed for idiopathic hypersomnia. This rare and d…

Cashu Finance·4 months ago
Blair Jackson
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Employees2.1K
IPO DateJul 16, 1991
ExchangeNASDAQ
Exchange NameNASDAQ
CurrencyUSD
Headquarters & Contact
AddressConnaught House
City / State / ZIPDublin, DU, D04 C5Y6
CountryIreland
Phone353 1 772 8000
Websitehttp://www.alkermes.com